B. Yassin-Rajkumar

Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.

David E. Anderson, P. van Damme, J. Langley, 2021, The Lancet. Infectious diseases.

Rapid and high seroprotection rates achieved with a tri-antigenic Hepatitis B vaccine in healthy young adults: Results from a Phase IV study.

David E. Anderson, F. Diaz-Mitoma, J. Atsmon, 2021, Vaccine.

Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.

Paige E. Waterman, N. Waters, W. Robinson, 2016, The Journal of infectious diseases.

The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine.

J. Langley, T. Vesikari, F. Diaz-Mitoma, 2023, Vaccine.

Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine

P. van Damme, R. Aronson, S. Faust, 2021, JAMA network open.